Mount Sinai Unveils New Sleep Research
Researchers will present studies at SLEEP 2024, covering CPAP withdrawal effects, hypoxic burden in OSA treatment, and new diagnostic tools.
Source: sleepreviewmag.com
📰 Excessive Daytime News
Excessive Daytime News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Excessive Daytime. Real-time updates on events, politics, business and more.
Axsome to Present New Sunosi Data at SLEEP 2023
Axsome Therapeutics Inc will present new data on Sunosi (solriamfetol) at SLEEP 2023, including results from the SHARP study.
United Kingdom Russell Rosenberg Hans Van Dongen Johannes Gutenberg Department Of Neurology Axsome Therapeutics Inc
Source: sleepreviewmag.com
Axsome Therapeutics, Inc.: Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical
Source: finanznachrichten.de
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
United States Stephenv Faraone Richardk Bogan Andrew Krystal Sk Biopharmaceuticals Co Ltd Axsome Therapeutics Inc
Source: globenewswire.com
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for...
Source: prnewswire.com
The Excessive Daytime Sleepiness Market Is Expected To Progress At A CAGR of 6.77% In The 7MM During The Study Period (2019-32), Assesses DelveInsight
/PRNewswire/ -- DelveInsights Excessive Daytime Sleepiness Market Insights report includes a comprehensive understanding of current treatment practices,...
Source: prnewswire.com
DelveInsight Business Research, LLP: The Excessive Daytime Sleepiness Market Is Expected To Progress At A CAGR of 6.77% In The 7MM During The Study Period (2019-32), Assesses DelveInsight
The Excessive Daytime Sleepiness market is expected to grow due to factors such as an increase in the patient population as the prevalence of underlying medical conditions rises, as well as
United States United Kingdom Shruti Thakur Wakix Pitolisant Bioprojet Pharma Prnewswire Delveinsight
Source: finanznachrichten.de
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with... | March 28, 2022
Source: marketscreener.com
? Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021
Jazz shares results from sleep medicine research and the development of novel therapeutic options for people living with sleep disorders DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals
United States Robert Iannone Jacqueline Kirby Andrean Flynn Sk Biopharmaceuticals Co Ltd Aerial Biopharma
Source: finanznachrichten.de